Stock Analysis, Dividends, Split History

DYN / Dynegy Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,849.65
Enterprise Value ($M)10,014.65
Book Value ($M)1,901.00
Book Value / Share13.17
Price / Book0.97
NCAV ($M)-8,354.00
NCAV / Share-57.86
Price / NCAV-0.22
Share Statistics
Common Stock Shares Outstanding 144,384,491
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 144,390,952
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Quick Ratio1.03
Current Ratio1.45
Income Statement (mra) ($M)
Electrical Generation Revenue4,842,000,000.00
Results Of Operations Sales Revenue To Unaffiliated Enterprises4,842,000,000.00
Operating Income-412.00
Net Income72.00
Earnings Per Share Basic0.37
Earnings Per Share Diluted0.36
Cash Flow Statement (mra) ($M)
Cash From Operations585.00
Cash from Investing-2,759.00
Cash from Financing-2,759.00
Identifiers and Descriptors
Central Index Key (CIK)1379895
Related CUSIPS
26817R116 26817R157 26817R958 26817G300 26817R908 26817R405

Split History

Stock splits are used by Dynegy Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Charah Solutions IPO: Undervalued, But Large Financial Risk

2018-06-09 seekingalpha
Leverage is very significant. The company will use the proceeds from the IPO to repay the debt. (93-0)

Vistra Energy (VST) Surges: Stock Moves 5.8% Higher

2018-04-10 zacks
Vistra Energy Corp. (VST - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $19.68–$21.13 in the past one-month time frame, witnessed a sharp increase yesterday. (24-0) featured highlights include: Weight Watchers, Match, Dynegy and HFF

2018-04-10 zacks
Chicago, IL – April 10, 2018 - Stocks in this week’s article Weight Watchers International, Inc. (WTW - Free Report) , Match Group, Inc. (MTCH - Free Report) , Dynegy Inc. and HFF, Inc. (HF - Free Report) . (32-0)

4 Hot Momentum Stocks for Impressive Returns

2018-04-09 zacks
When value or growth investing fails to fetch sustained profits, one should explore another time-tested winning strategy that simply bets on the frontrunner stocks. Translated, one of the most successful strategies today is to get in on momentum stocks at the right time. (9-0)

Robust Private Sector Hiring in March: 5 Top-Ranked Picks

2018-04-05 zacks
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000. (67-0)

CUSIP: 26817R108